Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diosmin + hesperidin
- Development stage
- Unknown
- Lead developer
- Hasan-Dermapharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hasanflon is a generic phlebotonic and vascular-protecting medication developed and marketed by Hasan-Dermapharm. It consists of a micronized purified flavonoid fraction (MPFF), typically containing 90% diosmin and 10% hesperidin. Hasanflon is indicated for the treatment of symptoms related to chronic venous insufficiency (CVI), such as heavy legs, pain, and nocturnal cramps, as well as for the management of acute hemorrhoidal attacks. The drug's mechanism of action involves increasing venous tone by prolonging the vasoconstrictor effect of noradrenaline on the venous wall, improving lymphatic drainage, and protecting the microcirculation by reducing capillary permeability and inhibiting inflammatory mediators.
- Brand names
- HasanflonHasanflon 500Hasanflon500Hasanflon-500
- Other names
- Micronized purified flavonoid fractionMPFF
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)AR (Adrenergic receptors)AcetylcholinesteraseCOMT (Catechol-O-methyltransferase)PDE (Phosphodiesterase family)AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on diosmin + hesperidin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diosmin + hesperidin.